S1PR1 and Cowden disease: The sphingosine-1-phosphate receptor-1 (S1P1) not required agonist ozanimod is a novel oral agent that has been shown in phase 2 clinical trials to be efficacious in treating UC, and trials of its use in CD are underway [94].